Innate Pharma shares are trading higher after the company announced it has entered into a strategic partnership with Swedish Orphan Biovitrum AB to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma.
Innate Pharma shares are trading higher after the company announced it has entered into a strategic partnership with Swedish Orphan Biovitrum AB to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma.